Clinical Trials /

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

NCT01805271

Description:

A significant number of patients relapse and eventually die, particularly if they were initially diagnosed with large nodes involvement and/or T3/4 diseases. When analyses focus on patients with ER+/Her2-negative breast cancer, with ≥4N+, 30% had relapsed at 5 years, emphasizing the need for new drugs in this setting (PACS01 data, UNICANCER internal data). Strong evidence suggests that cross-talk between the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and ER signaling is linked to hormone resistance in breast cancer patients. In the present study, we plan to evaluate the benefit from adding everolimus to standard endocrine treatments after three years of treatment for patient ER+/HER2- at high risk of relapse due to high nodes involvement (≥4) and/or persistent node involvement after neo-adjuvant chemotherapy. Genomic signatures have emerged during the last 10 years as a new and additive means to evaluate more precisely long term prognosis, and in some instances the amount of benefit from chemotherapy or endocrine therapy in the adjuvant setting. Therefore the UNIRAD study can be proposed to patients with 1-3 positive lymph nodes at primary surgery and a high risk of relapse with the EndoPredict test. This study is a unique opportunity to prove the efficacy of everolimus in adjuvant setting. The study could be practice changing in case of positive results and could allow improving outcome of breast cancer patients presenting high risk of metastatic relapse.

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
  • Official Title: Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy

Clinical Trial IDs

  • ORG STUDY ID: UNIRAD
  • SECONDARY ID: 2012-003187-44
  • SECONDARY ID: UC-0140/1208
  • NCT ID: NCT01805271

Conditions

  • Primary Non-metastatic Breast Cancer
  • Who Remain Disease-free

Interventions

DrugSynonymsArms
EverolimusAfinitorEverolimus
PlaceboPlacebo

Purpose

A significant number of patients relapse and eventually die, particularly if they were initially diagnosed with large nodes involvement and/or T3/4 diseases. When analyses focus on patients with ER+/Her2-negative breast cancer, with ≥4N+, 30% had relapsed at 5 years, emphasizing the need for new drugs in this setting (PACS01 data, UNICANCER internal data). Strong evidence suggests that cross-talk between the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and ER signaling is linked to hormone resistance in breast cancer patients. In the present study, we plan to evaluate the benefit from adding everolimus to standard endocrine treatments after three years of treatment for patient ER+/HER2- at high risk of relapse due to high nodes involvement (≥4) and/or persistent node involvement after neo-adjuvant chemotherapy. Genomic signatures have emerged during the last 10 years as a new and additive means to evaluate more precisely long term prognosis, and in some instances the amount of benefit from chemotherapy or endocrine therapy in the adjuvant setting. Therefore the UNIRAD study can be proposed to patients with 1-3 positive lymph nodes at primary surgery and a high risk of relapse with the EndoPredict test. This study is a unique opportunity to prove the efficacy of everolimus in adjuvant setting. The study could be practice changing in case of positive results and could allow improving outcome of breast cancer patients presenting high risk of metastatic relapse.

Trial Arms

NameTypeDescriptionInterventions
EverolimusExperimental1 or 2 tablets/day (i.e.5 or 10mg/day )
  • Everolimus
PlaceboPlacebo Comparator1 or 2 tablets/day
  • Placebo

Eligibility Criteria

        Inclusion Criteria:

          1. Female ≥ 18 years of age,

          2. Histologically proven invasive unilateral or bilateral breast cancer (regardless of
             the morphological subtype),

          3. Any T, M0

          4. Patient with high risk of relapse according to one of the conditions below:

               -  at least 4 positive lymph nodes if the patient had primary surgery

               -  or at least 1 positive lymph node if surgery was conducted after neo adjuvant
                  chemotherapy or hormone therapy of at least 3 months duration

               -  or 1-3 positive lymph nodes (pN1a, b, c) at primary surgery AND EPClin score ≥
                  3.32867 Note: Access to primary tumor for patients with 1-3 node positive is
                  mandatory. Patient with EPClin score < 3.32867 will not be randomized, but will
                  be followed yearly during 10 years.

          5. ER+ and HER2 negative : Hormone receptor positive is defined as any staining on the
             primary tumor, HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH
             non-amplified]

          6. Primary tumor completely resected (deep margins and overlying skin involvement allowed
             if fully resected)

          7. Patients who who will begin an adjuvant hormone therapy or have received a maximum of
             4 years of adjuvant hormone therapy. Hormone therapy could be either +/- LH-RH
             agonists, letrozole, anastrozole or exemestane.

          8. No clinically or radiologically detectable metastases at time of inclusion.

          9. WHO Performance status (ECOG) of 0 or 1.

         10. Adequate hematological function (neutrophil count ≥ 2x109/l; platelet count ≥
             100x109/l)

         11. Adequate hepatic function: AST and ALT ≤ 2.5 ULN, alkaline phosphatases ≤ 2.5 ULN,
             total bilirubin ≤ 2 ULN.

         12. Adequate renal function: serum creatinine ≤ 1.5 ULN.

         13. Signed written informed consent.

        Exclusion Criteria:

          1. Any local, or regional recurrence or metastatic disease.

          2. Any clinical or radiological suspicion of malignant or pre-malignant disease in the
             contralateral breast.

          3. Patients with pN1mi as sole nodal involvement

          4. Previous cancer (excepted basal cell carcinoma of the skin or in situ carcinoma of the
             cervix) in the preceding 5 years, including invasive contralateral breast cancer.

          5. Patient already included in another ongoing therapeutic trial involving an unlicensed
             drug for which follow-up is required.

          6. Patient who is pregnant or breast-feeding. Adequate birth control measures should be
             taken during the study treatment phase.

          7. Patient with significantly impaired lung function (e.g. Chronic Obstructive Pulmonary
             Disease, respiratory insufficiency, Interstitial Lung Disease)

          8. Positive serology for HIV infection or hepatitis C.

          9. Chronic carrier of HBV (positive Antigen HbsAg positive in the blood)

         10. Patient with chronic infection

         11. Uncontrolled diabetes defined as glycated haemoglobin , HbA1c>7%

         12. Uncontrolled hypercholesterolemia (cholesterol >300 mg/dl under adequate therapy).

         13. Known hypersensitivity to the active substance, to other rapamycin derivatives or to
             any of the excipients.

         14. Patient with other concurrent severe and/or uncontrolled medical disease or infection
             which could compromise participation in the study (e.g. patient who regularly require
             systemic steroids to control co-morbid disease).

         15. Patient with any psychological, familial, social or geographical condition which could
             potentially hamper compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:To evaluate the benefit from adding everolimus to standard endocrine treatments after two years of treatment on the disease-free survival (DFS)
Time Frame:2 years
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Assessment of impact of everolimus on the overall survival (OS), the Event Free Survival (EFS) and Distant Metastasis Free Survival (DMFS)
Time Frame:2 years
Safety Issue:
Description:
Measure:Assessment of impact of everolimus on DFS and OS in ER+,PR+ and ER+/PR- subgroups
Time Frame:2 years
Safety Issue:
Description:
Measure:Impact of everolimus on the incidence of secondary cancers
Time Frame:2 years
Safety Issue:
Description:
Measure:Assessment of the safety profiles for everolimus and hormone therapy combination.
Time Frame:2 years
Safety Issue:
Description:
Measure:Biology: Predictive value of mTOR activation markers on DFS: IHC analysis of primary tumor for pS6K and p4EBP.
Time Frame:2 years
Safety Issue:
Description:
Measure:quality of life sub-studies
Time Frame:2 years
Safety Issue:
Description:

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:UNICANCER

Trial Keywords

  • ER-positive HER2-negative

Last Updated

June 2, 2016